Neurofibromatosis Type 2

Neurofibromatosis Type 2 (NF2) is a rare, autosomal dominant genetic disorder characterized by the growth of noncancerous (benign) tumors in the nervous system. The hallmark feature is the development of bilateral vestibular schwannomas (acoustic neuromas) on the nerves responsible for hearing and balance, leading to progressive hearing loss.

NF2 is caused by a mutation in the NF2 gene located on chromosome 22q12.

1. This gene encodes the protein merlin (schwannomin), which acts as a tumor suppressor. Mutations can be inherited (autosomal dominant) or occur as de novo germline or somatic mosaic mutations.

The loss of functional merlin protein disrupts the regulation of cell signaling pathways, including the Hippo pathway and contact-dependent inhibition of cell growth. This allows for unregulated cellular proliferation, specifically in Schwann cells, meningeal cells, and glial cells, resulting in characteristic tumors.

The estimated prevalence is 1 in 25,000 to 1 in 40,0

1. Onset typically occurs in late adolescence or early adulthood, with equal distribution among genders.

• Family history of NF2
• De novo genetic mutation
• Mosaicism (often presents with milder, localized symptoms)

A. Early Symptoms

• Tinnitus


• Imbalance or unsteadiness


• Mild hearing loss B. Common Symptoms


• Bilateral hearing impairment


• Facial weakness or numbness


• Headaches


• Visual disturbances (cataracts) C. Advanced Symptoms


• Total deafness


• Difficulty swallowing


• Muscle atrophy (distal extremities)


• Ataxia D. Emergency Symptoms


• Increased intracranial pressure (nausea, projectile vomiting, papilledema)


• Sudden neurological deficit

• Ophthalmologic: Subcapsular cataracts, retinal hamartomas
• Neurologic: Sensorineural hearing loss, facial nerve palsy (CN VII), corneal anesthesia (CN V)
• Dermatologic: Cutaneous schwannomas, café-au-lait spots (less common than in NF1)

A. Clinical Assessment: Manchester criteria, Baser criteria.
B. Laboratory Testing: Genetic sequencing for NF2.
C. Imaging Studies: Gadolinium-enhanced MRI of the brain and spine.
D. Functional Tests: Audiometry, vestibular testing.
E. Biopsy Findings: Histopathology showing Antoni A and B areas in schwannomas.
F. Genetic Testing: Peripheral blood or tumor tissue analysis.
G. Differential Diagnosis: NF1, Schwannomatosis, Vestibular schwannoma (sporadic).

Test Name: NF2 Gene Sequencing
Type: Blood Test
Purpose: Mutation detection
Expected Findings: Pathogenic variant
Interpretation: Confirms diagnosis

• MRI Brain (with contrast): Gold standard to visualize bilateral vestibular schwannomas.
• MRI Spine: Essential to detect spinal ependymomas and meningiomas.

• Neurofibromatosis Type 1 (usually presents with neurofibromas and Lisch nodules)
• Schwannomatosis (painful schwannomas without vestibular involvement)
• Sporadic vestibular schwannoma (typically unilateral)

• Sensorineural hearing loss (bilateral)
• Hydrocephalus
• Spinal cord compression

A. Lifestyle Modifications: Avoidance of head trauma.
B. Preventive Measures: Genetic counseling.
C. Medical Treatment

• Bevacizumab (Anti-VEGF monoclonal antibody to inhibit tumor vascularization).

Variable. Younger onset and higher mutation load correlate with more aggressive disease. Lifelong monitoring is required.

Genetic counseling for families with known mutations. Prenatal and pre-implantation diagnosis.

The following homeopathic remedies have been historically indicated for symptoms associated with Neurofibromatosis Type 2. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

🔬 Lab Report Analyzer (Diagnostic Verification)

Upload your laboratory bloodwork PDF or paste your report text to automatically extract markers, detect units, and identify reference range variances related to Neurofibromatosis Type 2.